Tetratherix Says Joint Venture Partner Completes Series A Funding Round to Progress Prostate Spacing Clinical Trial, Shares Jump 5%

MT Newswires Live12:03

Tetratherix (ASX:TTX) said its joint venture partner, Tutelix, completed a Series A funding round from key investors led by a MedTech venture capital firm, bringing the total funds raised by the joint venture to around AU$5 million, allowing the joint venture to fast‑track the prostate spacing clinical trial to move towards an international pivotal study in the Australia and the US, according to a Tuesday Australian bourse filing.

The trial was designed to investigate the ability of the Tutelix spacer to be safely injected between the prostate and rectum to create and maintain space around the prostate.

Around 12 patients included the Tutelix spacer in their treatment, with the space generated by the spacer reducing the radiation dose received by the rectum in each patient. All 12 participants completed or are in the process of completing their radiation treatment plans.

Its shares jumped 5% in recent trading on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment